JP2020505046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505046A5 JP2020505046A5 JP2019541082A JP2019541082A JP2020505046A5 JP 2020505046 A5 JP2020505046 A5 JP 2020505046A5 JP 2019541082 A JP2019541082 A JP 2019541082A JP 2019541082 A JP2019541082 A JP 2019541082A JP 2020505046 A5 JP2020505046 A5 JP 2020505046A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- virus
- promoter
- seq
- recombinant virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims 39
- 238000012217 deletion Methods 0.000 claims 15
- 230000037430 deletion Effects 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 15
- 125000003729 nucleotide group Chemical group 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 230000003463 hyperproliferative effect Effects 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 108700026226 TATA Box Proteins 0.000 claims 11
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical class NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 241001135569 Human adenovirus 5 Species 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 230000001461 cytolytic effect Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452075P | 2017-01-30 | 2017-01-30 | |
| US62/452,075 | 2017-01-30 | ||
| PCT/US2018/016025 WO2018140970A1 (en) | 2017-01-30 | 2018-01-30 | Tumor selective tata-box and caat-box mutants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505046A JP2020505046A (ja) | 2020-02-20 |
| JP2020505046A5 true JP2020505046A5 (enExample) | 2021-03-11 |
| JP7242534B2 JP7242534B2 (ja) | 2023-03-20 |
Family
ID=62978967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541082A Active JP7242534B2 (ja) | 2017-01-30 | 2018-01-30 | 腫瘍選択的なｔａｔａボックスおよびｃａａｔボックスの変異体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190352669A1 (enExample) |
| EP (1) | EP3573632B1 (enExample) |
| JP (1) | JP7242534B2 (enExample) |
| KR (2) | KR102607220B1 (enExample) |
| CN (1) | CN110741081B (enExample) |
| AU (1) | AU2018212017B2 (enExample) |
| BR (1) | BR112019015514A2 (enExample) |
| CA (1) | CA3052086A1 (enExample) |
| EA (1) | EA201991806A1 (enExample) |
| IL (1) | IL268289B2 (enExample) |
| MX (1) | MX2019008922A (enExample) |
| SG (1) | SG11201906976YA (enExample) |
| WO (1) | WO2018140970A1 (enExample) |
| ZA (1) | ZA201905070B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EP3610003A4 (en) | 2017-04-10 | 2021-01-06 | EpicentRx, Inc. | RECOMBINANT VIRUS PRODUCTION PROCESS |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP4554559A1 (en) | 2022-07-13 | 2025-05-21 | EpicentRx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1190901A (en) * | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| EP1381276A4 (en) * | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION |
| CN1597939A (zh) * | 2001-11-15 | 2005-03-23 | 杭州中肽生化有限公司 | 多功能抗癌重组腺病毒 |
| CN101319215B (zh) * | 2008-07-01 | 2010-12-22 | 郑骏年 | 人肿瘤特异性Ki67基因启动子 |
| FI20090030A0 (fi) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Onkolyyttiset virukset |
| PT2403951E (pt) * | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| KR101427200B1 (ko) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | 아데노바이러스 생산 신규 세포주 및 그의 용도 |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| CN120796389A (zh) * | 2017-05-26 | 2025-10-17 | 埃皮森特Rx股份有限公司 | 携带转基因的重组腺病毒 |
-
2018
- 2018-01-30 US US16/482,049 patent/US20190352669A1/en not_active Abandoned
- 2018-01-30 EA EA201991806A patent/EA201991806A1/ru unknown
- 2018-01-30 BR BR112019015514A patent/BR112019015514A2/pt unknown
- 2018-01-30 KR KR1020197025497A patent/KR102607220B1/ko active Active
- 2018-01-30 CA CA3052086A patent/CA3052086A1/en active Pending
- 2018-01-30 IL IL268289A patent/IL268289B2/en unknown
- 2018-01-30 EP EP18744813.9A patent/EP3573632B1/en active Active
- 2018-01-30 KR KR1020237040310A patent/KR102880548B1/ko active Active
- 2018-01-30 AU AU2018212017A patent/AU2018212017B2/en active Active
- 2018-01-30 CN CN201880021788.0A patent/CN110741081B/zh active Active
- 2018-01-30 MX MX2019008922A patent/MX2019008922A/es unknown
- 2018-01-30 WO PCT/US2018/016025 patent/WO2018140970A1/en not_active Ceased
- 2018-01-30 SG SG11201906976YA patent/SG11201906976YA/en unknown
- 2018-01-30 JP JP2019541082A patent/JP7242534B2/ja active Active
-
2019
- 2019-07-31 ZA ZA2019/05070A patent/ZA201905070B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505046A5 (enExample) | ||
| US6677156B2 (en) | Non-adenoviral gene product-based complementing cells for adenoviral vectors | |
| JP2020505049A5 (enExample) | ||
| JP6009357B2 (ja) | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 | |
| JP2012016359A (ja) | Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター | |
| JP2010525805A5 (enExample) | ||
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| CA2640528A1 (en) | Oncolytic adenoviruses for cancer treatment | |
| JP2014207903A5 (enExample) | ||
| WO2011119925A3 (en) | Synthetic herpes simplex viruses for treatment of cancers | |
| JP2008526238A (ja) | 癌標的ウイルスベクター | |
| US12233096B2 (en) | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells | |
| CN110741081A (zh) | 肿瘤选择性tata盒和caat盒突变体 | |
| Hughes et al. | Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus | |
| WO2012163119A1 (zh) | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 | |
| Peter et al. | A novel attenuated replication-competent adenovirus for melanoma therapy | |
| NO330666B1 (no) | Selektivt replikerende, rekombinant virusvektor, farmasoytisk formulering, fremgangsmate for dreping av en celle ex vivo med en reaksjonsveimangel, anvendelse av en selektivt replikerende viral vektor for fremstilling av et farmasoytisk preparat, samt fremgangsmate for fremstilling av en selektivt replikerende viral vektor. | |
| Liu et al. | Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L | |
| JP6235697B2 (ja) | 変異ワクシニアウイルス株、その使用およびそれを作製する方法 | |
| CN103562386A (zh) | Reic表达腺病毒载体 | |
| Wu et al. | Viral delivery for gene therapy against cell movement in cancer | |
| Zhu et al. | Targeting gene expression to tumor cells with loss of wild-type p53 function | |
| WO2023122882A1 (zh) | 双特异性t细胞衔接器、其重组溶瘤病毒及其用途 | |
| Heiniö et al. | Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs | |
| WO2006125381A1 (en) | Tumor targeting gene-virus zd55-il-24, construction method and application thereof |